Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
Frontiers in Pharmacology · 31.05.2023 · 14
DOI: 10.3389/fphar.2023.1187066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.05.2023. Verfasst von Bharathi M Rajamani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Christian Medical College, Vellore, India. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Introduction
The ligand-activated transcription factors, nuclear hormone receptors (NHRs), remain unexplored in hematological malignancies except for retinoic acid receptor alpha ( RARA ).
Methods
Here we profiled the expression of various NHRs and their coregulators in Chronic myeloid leukemia (CML) cell lines and identified a significant differential expression pattern between inherently imatinib mesylate (IM)-sensitive and resistant cell lines.
Results
Retinoid-X-receptor alpha ( RXRA ) was downregulated in CML cell lines inherently resistant to IM and in primary CML CD34 + cells. Pre-treatment with clinically relevant RXRA ligands improved sensitivity to IM in-vitro in both CML cell lines and primary CML cells. This combination effectively reduced the viability and colony-forming capacity of CML CD34 + cells in-vitro. In-vivo, this combination reduced leukemic burden and prolonged survival. Overexpression (OE) of RXRA inhibited proliferation and improved sensitivity to IM in-vitro . In-vivo, RXRA OE cells showed reduced engraftment of cells in the bone marrow, improved sensitivity to IM, and prolonged survival. Both RXRA OE and ligand treatment markedly reduced BCR::ABL1 downstream kinase activation, activating apoptotic cascades and improving sensitivity to IM. Importantly, RXRA OE also led to the disruption of the oxidative capacity of these cells.
Conclusion
Combining IM with clinically available RXRA ligands could form an alternative treatment strategy in CML patients with suboptimal response to IM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Christian Medical College, Vellore, India.
- Department of Biotechnology, Thiruvalluvar University, Vellore, India.
- Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India.
- Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India.
- Manipal Academy of Higher Education, Manipal, India.
- Centre for Stem Cell Research (CSCR), A Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, India.
Förderung
- Wellcome Trust
Zitieren
APA
Rajamani, B. M., Illangeswaran, R. S. S., Benjamin, E. S. B., Balakrishnan, B., Jebanesan, D. Z. P., Das, S., Pai, A. A., Vidhyadharan, R. T., Mohan, A., Karathedath, S., Abraham, A., Mathews, V., Velayudhan, S. R., & Balasubramanian, P. (2023). Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1187066
Vancouver
Rajamani BM, Illangeswaran RSS, Benjamin ESB, Balakrishnan B, Jebanesan DZP, Das S, et al. Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1187066
BibTeX
@article{Rajamani2023,
author = {Rajamani, Bharathi M and Illangeswaran, Raveen Stephen Stallon and Benjamin, Esther Sathya Bama and Balakrishnan, Balaji and Jebanesan, Daniel Zechariah Paul and Das, Saswati and Pai, Aswin Anand and Vidhyadharan, Rakhi Thalayattu and Mohan, Ajith and Karathedath, Sreeja and Abraham, Aby and Mathews, Vikram and Velayudhan, Shaji R and Balasubramanian, Poonkuzhali},
title = {Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1187066}
}
EUVIMED